ATAI

#2139
AtaiBeckley Inc. Common Stock
4.3300 USD
-0.23%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
4.3300
4.3300
Jahresspanne
3.2700
5.5000
Tagesänderung
-0.23%
Monatliche Änderung
+28.49%
6 month change
+9.62%
Jahresänderung
+9.62%
Vorheriger Schlusskurs
4.3400
Eröffnung
4.3300
Tief
4.3300
High
4.3300
Volumen
64
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik
Vierteljährlich Jährlich
  • Market Capitalization 1.5794 B
  • Employee 99
  • Founded 2018
  • CEO Florian Brand
  • Website www.ataibeckley.com
  • Headquarter Delaware, United States
  • FIGI BBG0107FR3K9
  • Industry Biotechnologie
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
-1.41
Preis-Umsatz-Verhältnis
226.59

AtaiBeckley Inc

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.

Nachrichten